The Federal Circuit in a precedential opinion in Osai Pharmaceuticals, LLC v Apotex et al (Fed. Cir., October 4, 2019) http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/18-1925.Opinion.10-4-2019.pdfreversed the USPTO's determination of obviousness in an IPR for patent claims directed to the treatment of non-small cell lung cancer (NSCLC). Just reading the background of the first three or four pages of the decision, it was already apparent that the Court was not going to be affirming the PTAB's decision. Notably:

David Longo will participate in the US Bar/JPO Liaison Council Meeting as a Virginia State Bar delegate on October 17-18th, in Tokyo, Japan.

Several Oblon attorneys will be attending the 2019 AIPLA Annual Meeting on October 24-26th at the Gaylord National Resort & Convention Center.

Oblon is a sponsor of the SEBIO Investor & Partnering Forum 2019 that will be held on November 6-7th at The Biltmore in Miami-Coral Gables, Florida. The conference provides an unparalleled opportunity to meet key decision makers in the regional and national life science and medical technology communities. More than 300 biotech and medtech investors, corporate executives, university representatives, and entrepreneurs will attend this year.

Oblon professionals took International Guests to a Nationals baseball game at Nats Park in Washington, DC.

Eleven Oblon attorneys have been named to the 2020 edition of Best Lawyers in America.

Today, Oblon launched its Life Sciences blog, www.lifesciencesipblog.com , which is designed to report and comment on Intellectual property matters related to the life sciences industry.